Abstract
Ruxolitinib is a Janus kinase (JAK) inhibitor used in the treatment of myelofibrosis. In the last six years, there have been four cases of Sweet syndrome (SS) reported in patients with ruxolitinib-treated myelofibrosis. (1-4) To our knowledge, this is the first case reported on a ruxolitinib-associated neutrophilic dermatosis presenting with a pathergy phenomenon at a post-operative wound site, accompanied by mucosal involvement.
| Original language | English |
|---|---|
| Pages (from-to) | e607-e609 |
| Number of pages | 3 |
| Journal | Australasian Journal of Dermatology |
| Volume | 62 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Nov 2021 |
Keywords
- neutrophilic dermatosis
- pathergy
- pyoderma gangrenosum
- ruxolitinib
- sweet syndrome
- tyrosine kinase inhibitor
Fingerprint
Dive into the research topics of 'A neutrophilic dermatosis following treatment of myelofibrosis with ruxolitinib: An emerging phenomenon?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver